1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Shuda Xia
Shuda Xia
Articles (296) 

Stocks That Fell to 3-Year Lows in the Week of Sept. 13

Altria Group Inc. (MO), BioMarin Pharmaceutical Inc. (BMRN), Pennant Park Investment Corp. (PNNT), and Rigel Pharmaceuticals Inc. (RIGL) have declined to their three-year lows

September 15, 2019 | About:

Altria Group Inc. (NYSE:MO), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Pennant Park Investment Corp. (NASDAQ:PNNT), and Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) have declined to their three-year lows.

Altria Group Inc. (NYSE:MO) declined to $42.01

The prices of Altria Group Inc. (NYSE:MO) shares have declined to $42.01 on Sept. 13, which is only 0.1% above the 3-year low of $41.97.

Altria Group Inc. is an American international tobacco corporation. The company is one of the world’s largest producers and marketers of cigarettes and other tobacco products. The company is the parent company of several companies, including Smokeless Tobacco Company Inc. and John Middleton Inc.

Altria Group Inc. has a market cap of $78.48 billion; its shares were traded around $42.01 with a P/E ratio of 12.49 and P/S ratio of 3.13. The trailing 12-month dividend yield of Altria Group Inc. stocks is 7.62%. The forward dividend yield of Altria Group Inc. stocks is 7.56%. Altria Group Inc. had an annual average earnings growth of 10.20% over the past 10 years.

On Aug. 27 Altria Group Inc. announced that it is in discussions with Philip Morris International Inc. regarding a potential all-stock, merger of equals. However, there is no assurance that any agreement or transaction will result from these discussions. Furthermore, there can also be no assurance that if an agreement is reached, that a transaction will be completed.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) declined to $72.65

The prices of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares have declined to $72.65 on Sept. 13, which is only 2.5% above the 3-year low of $70.82.

BioMarin Pharmaceutical Inc. is an American biotechnology company that focuses on enzyme replacement therapies. The company was the first to provide therapeutics for mucopolysaccharidosis type I by manufacturing laronidase. The company was also the first to provide therapeutics for phenylketonuria.

BioMarin Pharmaceutical Inc. has a market cap of $13.04 billion; its shares were traded around $72.65 with and P/S ratio of 8.51.

On Aug. 1 BioMarin Pharmaceutical Inc. announced financial results for the second quarter of 2019. Revenue for the quarter totaled $387.8 million, a 4% increase compared to revenues of $372.8 million during the same period prior year. GAAP net loss for the quarter was $37.4 million, compared to a net loss of $16.8 million during the same quarter prior year.

Pennant Park Investment Corp. (NASDAQ:PNNT) declined to $6.40

The prices of Pennant Park Investment Corp. (NASDAQ:PNNT) shares have declined to $6.40 on Sept. 13, which is only 3.8% above the 3-year low of $6.16.

Pennant Park Investment Corp. is an American business development company that primarily invests in U.S. middle-market private companies. The company invests in the form of first lien secured debt, second lien secured debt, subordinated debt, and equity investments. The company is managed by PennantPark Investment Advisers LLC.

Pennant Park Investment Corp. has a market cap of $429.089 million; its shares were traded around $6.40 with a P/E ratio of 22.07 and P/S ratio of 15.50. The trailing 12-month dividend yield of Pennant Park Investment Corp. stocks is 11.25%. The forward dividend yield of Pennant Park Investment Corp. stocks is 11.39%.

On Sept. 5 Pennant Park Investment Corp. declared its fourth fiscal quarter dividend of 18 cents per share. The dividend will be payable on Oct. 1 to stockholders of record at the close of business on Sept. 17.

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) declined to $1.65

The prices of Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) shares have declined to $1.65 on Sept. 13, which is only 3.0% above the 3-year low of $1.60.

Rigel Pharmaceuticals Inc. is an American biotechnology company that is primarily focused on developing small particle drugs to treat immune and hematologic disorders, cancers, and rare diseases. The company’s research focuses on signaling pathways that are critical to disease mechanisms.

Rigel Pharmaceuticals Inc. has a market cap of $276.555 million; its shares were traded around $1.65 with and P/S ratio of 4.19. Rigel Pharmaceuticals Inc. had an annual average earnings growth of 13.70% over the past 5 years.

On Aug. 6 Rigel Pharmaceuticals Inc. reported financial results for the second quarter of 2019 ended June 30. Net loss for the quarter was $20.6 million, or 12 cents per share, compared to a net loss of $25.6 million, or 16 cents per share, during the same quarter prior year. Net product sales from TAVALISSE was $10.2 million, compared to $1.8 million during the same period prior year. Total costs for the quarter was $31.7 million, compared to $27.9 during the same quarter prior year.

Disclosure: I do not own stock in any of the companies mentioned in the article.


Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by Shuda Xia


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)